This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunesis Announces Clinical Trial Updates And 2013 Milestones At The 31st Annual JP Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, provided a corporate update, including a clinical trial enrollment update and overview of 2013 major corporate milestones, in a presentation at the 31 st Annual J.P. Morgan Healthcare Conference in San Francisco. A webcast replay of the presentation, which was delivered today, January 10, at 12:00 PM Pacific Time, is archived on the Sunesis website at http://ir.sunesis.com and will be available for two weeks.
Sunesis Pharmaceuticals, Inc. Logo
VALOR Logo

"Last year was a very productive period for Sunesis, with meaningful progress in our vosaroxin studies, including our pivotal, Phase 3 VALOR trial," said Daniel Swisher, Chief Executive Officer of Sunesis. "Looking ahead in 2013, we see a number of value-creating milestones, particularly with the advancement of vosaroxin toward commercialization. It is our goal to see vosaroxin, an unpartnered asset and one of the most advanced and promising therapies in development for AML today, change the global standard of care in this disease. With continued support and enthusiasm from our investigators and stakeholders, as well as a strong balance sheet, we remain well positioned to achieve this goal."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs